• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Trinity Capital Inc. Expands Life Sciences Presence to East Coast with John Orlando as Managing Director

    3/3/25 7:30:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance
    Get the next $TRIN alert in real time by email

    PHOENIX, March 3, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of John Orlando as Managing Director of Life Sciences, based in Boston. Mr. Orlando, an established leader with over a decade of experience in venture lending, has built a strong reputation as a trusted partner within the Life Sciences industry.

    John Orlando, Managing Director of Life Sciences

    "We are thrilled to welcome John to our team," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We believe his industry experience and deep relationships will help Trinity grow our portfolio and expand our presence in the Northeast region."

    Mr. Orlando joins Trinity from Flagship Pioneering, where he led a centralized debt advisory function, instructing portfolio companies on strategic debt financing alternatives. Prior to Flagship, Mr. Orlando provided debt and banking services to venture-backed companies at J.P. Morgan and Pacific Western Bank.

    "I am delighted to join Trinity Capital and their fantastic team in the Life Sciences sector," said Mr. Orlando. "Trinity has been incredibly active lending to high-growth companies, and I am excited to help further bolster their efforts."

    About Trinity Capital Inc.

    Trinity Capital Inc. (NASDAQ:TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in Phoenix, Arizona, the firm has an international footprint, supported by a dedicated team of strategically located investment professionals. For more information, visit the company's website at trinitycapital.com and stay connected by following us on LinkedIn and X (formerly Twitter).

    (PRNewsfoto/Trinity Capital Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-expands-life-sciences-presence-to-east-coast-with-john-orlando-as-managing-director-302389054.html

    SOURCE Trinity Capital Inc.

    Get the next $TRIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIN

    DatePrice TargetRatingAnalyst
    5/13/2025$16.00Buy
    B. Riley Securities
    12/2/2024$13.00Equal Weight → Underweight
    Wells Fargo
    8/22/2023$15.50Neutral → Buy
    Compass Point
    8/7/2023$15.00Underperform → Mkt Perform
    Keefe Bruyette
    7/5/2023$15.00Buy
    Jefferies
    3/13/2023$13.50 → $11.00Mkt Perform → Underperform
    Keefe Bruyette
    11/7/2022$30.00Positive → Neutral
    Susquehanna
    11/4/2022$16.00 → $12.50Outperform → Mkt Perform
    Keefe Bruyette
    More analyst ratings